Recent News for TAK - Takeda Pharmaceutical Company Limited

Date Title
Apr 7 Kamada says amendment to Takeda deal could accelerate payments
Apr 5 Why Molecular Templates Stock Crashed Today
Apr 5 Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies
Apr 1 Takeda Hosts Wave 1 Pipeline Market Call
Apr 1 Takeda: Why Now Is The Time For Taking The Opportunity For Getting On The Takeda A-Train
Mar 31 Takeda Is A Mediocre Income Investment
Mar 31 Takeda offloads select OTC and non-core assets to Orifarm for $670M
Mar 31 Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
Mar 31 Takeda finalizes sale of Japan consumer health unit to Blackstone
Mar 31 Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
Mar 30 Takeda, BridGene To Pursue Undruggable Neurodegenerative Targets
Mar 30 Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday
Mar 29 Alphabet, Baidu, NXP Semiconductors, Pinterest, Pure Storage — What Cathie Wood's Ark Bought And Sold On Friday
Mar 26 Novadiscovery inks new clinical simulation collaboration with Takeda
Mar 26 Alibaba, Amazon, Palantir, Google, Takeda, Unity — What Cathie Wood's Ark Bought And Sold On Thursday
Mar 25 Takeda starts regulatory filings for dengue vaccine candidate in EU
Mar 25 Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Mar 22 Evotec, Takeda form strategic RNA targeting alliance
Mar 18 Anima Attracts Takeda In Multibillion-Dollar mRNA Translation Modulators Deal For Neurological Diseases
Mar 17 Takeda’s lung cancer therapy approved for new indication in Canada
Mar 15 Novavax CEO: COVID-19 vaccine manufacturing hurdles won't go away anytime soon
Mar 15 IDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing Capacity
Mar 15 Phase 3 analysis confirms efficacy of Takeda's maribavir in transplant recipients
Mar 15 Takeda grants J&J German production capacity for COVID-19 shot
Mar 15 Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
Back to the Main TAK Page...